Auditor questions Marea and M2 viability even after cash more than doubles

Ernst & Young has told stockholders of Lisata Therapeutics that the combined accounts of Marea Therapeutics and M2 Therapeutics carry an unusual caveat: the auditor doubts the two companies can keep operating as a business for the foreseeable future. The report is dated 12 November 2026 and covers the combined financial statements for 2025 and 2024.

EY points to two features of the accounts: repeated losses and a net stockholders' deficit, meaning liabilities exceed assets. The accumulated deficit stood at $141.3M at 31 December 2025. Over the same period the companies' cash rose to $75.3M, from $31.6M a year earlier.

The contrast matters for anyone sizing up the pair commercially. A balance that more than doubled in a year did not persuade the auditor to drop the warning, which suggests the cash position was weighed against the scale of losses and the deficit rather than taken at face value.

By way of context, an auditor's warning of this kind says the accounts raise significant questions about an entity's continuity. It is not a prediction that the entity will fail. The material available does not set out how Marea and M2 intend to address the concern, and it gives no detail on funding plans or on what the warning means for their programmes.